- Home
- HCKT vs SLGL Comparison
HCKT vs SLGL Comparison
Compare HCKT & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HCKT | SLGL |
|---|---|---|
| Founded | 1991 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 284.4M | 255.2M |
| IPO Year | 1998 | 2016 |
Fundamental Metrics
Financial Performance| Metric | HCKT | SLGL |
|---|---|---|
| Price | $9.73 | $77.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $17.00 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 338.3K | 23.7K |
| Earning Date | 05-05-2026 | 05-22-2026 |
| Dividend Yield | ★ 3.67% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $285,862,000.00 | N/A |
| Revenue This Year | $2.55 | N/A |
| Revenue Next Year | $5.07 | $223.84 |
| P/E Ratio | $54.71 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.16 | $10.77 |
| 52 Week High | $23.72 | $97.97 |
Technical Indicators
Market Signals| Indicator | HCKT | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 43.17 | 56.54 |
| Support Level | $9.60 | $67.53 |
| Resistance Level | $14.49 | $95.83 |
| Average True Range (ATR) | 0.54 | 5.88 |
| MACD | -0.06 | 0.69 |
| Stochastic Oscillator | 29.25 | 48.57 |
Price Performance
Historical ComparisonAbout HCKT Hackett Group Inc (The).
The Hackett Group Inc is an IP platform-based Generative Artificial Intelligence (Gen AI) strategic consulting and executive advisory digital transformation firm. The Hackett Group provides dedicated expertise in Gen AI-enabled enterprise transformation services across the front, mid and back office areas, including its highly recognized Oracle, SAP, OneStream and Coupa implementation offerings. It operates in three segments Oracle Solutions, SAP Solutions, and Global S&BT. It generates the majority of its revenue from the Global S&BT segment in the United States.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.